Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001384998 | SCV001584705 | pathogenic | not provided | 2024-12-24 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asp1820Valfs*60) in the SZT2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SZT2 are known to be pathogenic (PMID: 23932106, 27248490, 28556953). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SZT2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1072312). For these reasons, this variant has been classified as Pathogenic. |
Prevention |
RCV004728700 | SCV005336434 | likely pathogenic | SZT2-related disorder | 2024-07-17 | no assertion criteria provided | clinical testing | The SZT2 c.5459_5462delACAG variant is predicted to result in a frameshift and premature protein termination (p.Asp1820Valfs*60). To our knowledge, this variant has not been reported in the literature or in a large population database, indicating it is rare. Frameshift variants in SZT2 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |